ArticleEuropean journal of hospital pharmacy : science and practice2024
Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients.
Article in European journal of hospital pharmacy : science and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis.European journal of clinical pharmacology · 2023Pooled it
- Electronic health record-based prediction models for in-hospital adverse drug event diagnosis or prognosis: a systematic review.Journal of the American Medical Informatics Association : JAMIA · 2023Pooled it
- Clinical Impact of Linezolid Therapeutic Drug Monitoring on the Tolerability of Prolonged Courses in the Outpatient Setting.Open forum infectious diseases · 2026Trial
- Development and validation of a nomogram for predicting thrombocytopenia in sepsis patients treated with linezolid.BMC pharmacology & toxicology · 2026Article
- Prediction model of thrombocytopenia on patients using linezolid: a ranked-based covariate selection with multi-center data.Frontiers in pharmacology · 2026Article
- Risk factors of linezolid-associated hyponatremia from a retrospective case-control study: decreased serum albumin as a selective predictor in elder patients.Annals of medicine · 2025Article
- Renal function affects the plasma concentration and hematological toxicity of linezolid in elderly patients: a propensity-matched cohort analysis.BMC geriatrics · 2025Article
- Towards a prescribing monitoring system for medication safety evaluation within electronic health records: a scoping review.BMC medical informatics and decision making · 2025Article
- Development and validation of a risk prediction model for meropenem-related thrombocytopenia in patients with pulmonary infection.BMC pharmacology & toxicology · 2025Article
- Development and validation of a nomogram to predict linezolid-induced thrombocytopenia in hospitalized adults.BMC pharmacology & toxicology · 2025Article
- Risk Stratification for Cephalosporin-Induced Thrombocytopenia: Development and Validation of a Multidimensional Predictive Model in Older Adults.Risk management and healthcare policy · 2025Article
- Using Machine Learning to Predict Linezolid-Associated Thrombocytopenia.Infection and drug resistance · 2025Article
- A nomogram incorporating linezolid and metabolite concentrations for predicting linezolid induced thrombocytopenia in patients with renal impairment.Scientific reports · 2024Article
- Development and validation of a risk prediction model for linezolid-induced anemia in elderly patients: a retrospective cohort study.Therapeutic advances in drug safety · 2024Article
- Prediction of risk factors for linezolid-induced thrombocytopenia based on neural network model.Frontiers in pharmacology · 2024Article
- A risk prediction model of linezolid-induced thrombocytopenia for elderly patients with chronic kidney disease is urgently needed.European journal of hospital pharmacy : science and practice · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLinezolid is the first oxazolidinone antimicrobial agent developed for treating multi-drug-resistant gram-positive bacterial infections. The study aimed to investigate the risk factors of linezolid (LI)-induced thrombocytopenia (LI-TP) and to develop and validate a risk prediction model to identify elderly patients at high risk of developing LI-TP during linezolid therapy.
methodsA retrospective cohort study was performed at Zhongshan Hospital, FuDan University, China. The study involved elderly Chinese patients aged ≥65 years administered with linezolid (600 mg) twice a day between January 2015 and April 2021. We collected the patients' clinical characteristics and demographic data from electronic medical records, and compared the differences between LI-TP patients and those who had not developed thrombocytopenia (NO-TP) after linezolid treatment. The risk prediction model was developed based on the regression coefficient generated from logistic regression model.
resultsA total of 343 inpatients were enrolled from January 2015 to August 2020 and were used as the training set. Among them, 67 (19.5%) developed LI-TP. Multivariate logistic regression analysis revealed that baseline platelet counts <150×10
conclusionsThese findings indicate that duration of linezolid therapy, age, eGFR, ICU admittance, baseline platelet counts, concomitant piperacillin-tazobactam were significantly associated with LI-TP in elderly patients. A risk prediction model based on these risk factors showed a good discriminative performance and may be useful for clinicians to identify patients at high risk of developing LI-TP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.